More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader said at a major drug industry conference last week.
340B ESP Product Development Lead Andrew Brownlee gave a presentation Friday at Informa’s 2022 Medicaid Drug Rebate Program Summit in Chicago on 340B ESP’s status and what Second Sight and its parent, Berkeley Research Group, have learned and can now predict. 340B ESP Founder and Business Development Lead Aaron Vandervelde gave a similar presentation in May during 340B Report’s inaugural webinar for subscribers about the platform.
More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader said at a major drug industry conference last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
